Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Corticosteroids in ophthalmology.

U Pleyer1, Z Sherif

  • 1Department of Ophthalmology, University Hospital Charité, Campus Virchow-Klinik, Augustenburger Platz 1, 13353 Berlin, Germany. uwe.pleyer@charite.de

Ernst Schering Research Foundation Workshop
|October 3, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[ChatGPT and the German board examination for ophthalmology: an evaluation].

Die Ophthalmologie·2024
Same author

[Diagnostics and treatment of ocular toxoplasmosis : Results of a survey].

Die Ophthalmologie·2022
Same author

[Are "pachychoroid spectrum disorders" a topic for CME?]

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·2021
Same author

[Intraocular inflammation with brolucizumab use : Patient management-diagnosis-therapy].

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·2021
Same author

[Red eye somewhat different : From local finding to systemic diagnosis].

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·2020
Same author

[Long version on the S3 guidelines for axial spondyloarthritis including Bechterew's disease and early forms, Update 2019 : Evidence-based guidelines of the German Society for Rheumatology (DGRh) and participating medical scientific specialist societies and other organizations].

Zeitschrift fur Rheumatologie·2019
Same journal

Stem cells in reproduction and in the brain. Proceedings of a workshop. September 1-3, 2005. Kobe, Japan.

Ernst Schering Research Foundation workshop·2007
Same journal

Can cell systems biology rescue drug discovery?

Ernst Schering Research Foundation workshop·2007
Same journal

Applying a causal framework to system modeling.

Ernst Schering Research Foundation workshop·2007
Same journal

A plea for more theory in molecular biology.

Ernst Schering Research Foundation workshop·2007
Same journal

Network genomics.

Ernst Schering Research Foundation workshop·2007
Same journal

The theory of biological robustness and its implication in cancer.

Ernst Schering Research Foundation workshop·2007
See all related articles

Corticosteroids remain the primary treatment for inflammatory eye conditions due to their potency. Future research focuses on developing safer corticosteroid drugs and advanced drug-release systems to minimize side effects.

Area of Science:

  • Ophthalmology
  • Pharmacology
  • Drug Development

Background:

  • Corticosteroids have been a cornerstone in treating acute inflammatory eye disorders for 50 years.
  • Their broad anti-inflammatory actions contribute to high efficacy but also significant side effects.

Purpose of the Study:

  • To review the current role of corticosteroids in ophthalmology.
  • To discuss the challenges and future directions in corticosteroid therapy for ocular inflammation.

Main Methods:

  • Literature review of corticosteroid use in ophthalmology.
  • Analysis of efficacy and side effect profiles.
  • Exploration of potential future therapeutic strategies.

Main Results:

Related Experiment Videos

  • Corticosteroids are highly effective for acute inflammatory eye conditions.
  • Broad-spectrum activity leads to potent anti-inflammatory effects.
  • Significant side effects necessitate careful management and alternative approaches.

    • Conclusions:

    • Corticosteroids are indispensable for managing acute ocular inflammation.
    • Development of safer corticosteroids with a higher therapeutic index is crucial.
    • Long-term drug-release systems offer a promising avenue for improved treatment delivery and reduced toxicity.